Wockhardt is currently trading at Rs 1003.00, up by 11.85 points or 1.20% from its previous closing of Rs 991.15 on the BSE.
The scrip opened at Rs 993.70 and has touched a high and low of Rs 1013.80 and Rs 972.70 respectively. So far 157064 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 1748.20 on 02-Dec-2015 and a 52 week low of Rs 706.35 on 12-Feb-2016.
Last one week high and low of the scrip stood at Rs 1129.00 and Rs 911.05 respectively. The current market cap of the company is Rs 11006.69 crore.
The promoters holding in the company stood at 74.19%, while Institutions and Non-Institutions held 10.14% and 15.54% respectively.
The US health regulator has made observations in its Establishment Inspection Report (EIR) for Wockhardt’s three units in Maharashtra and ban on exports from the facilities to the US will continue. The company’s three facilities - Chikalthana and two units at Waluj in Maharashtra - have received EIR with observations. EIR is given to an establishment after the completion of the inspection by the US Food and Drug Administration (USFDA).
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.90 |
| Dr. Reddys Lab | 1237.60 |
| Cipla | 1237.10 |
| Zydus Lifesciences | 941.00 |
| Lupin | 2328.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: